Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
07/2003
07/15/2003US6593290 Treatment of inner ear hair cells
07/15/2003US6593133 Neurotrophic factors
07/15/2003US6592896 Medicinal composition and method of using it
07/15/2003CA2316731C Concentrated and stabilized antipyretic compound for veterinary use to be added to animal feed and process for adding the said compound to animal drinking water
07/10/2003WO2003055511A1 Liquid composition of modified factor vii polypeptides
07/10/2003WO2003055466A1 Microemulsion preconcentrate
07/10/2003WO2003055442A2 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
07/10/2003US20030130338 Method of treatment
07/10/2003US20030130291 Dissolving in solvents; precipitation; isolation; sleep disorders
07/10/2003US20030130286 Antiproliferative agents; anticancer agents; central nervous system disorders; antiarthritic agents
07/10/2003US20030130280 Analyzing, prevention blood phosphorylation
07/10/2003US20030130254 Respiratory system disorders; antihistamines; antiarthritic agents
07/10/2003US20030130250 Methods to mobilize progenitor/stem cells
07/10/2003CA2470313A1 Liquid composition of modified factor vii polypeptides
07/10/2003CA2463738A1 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
07/09/2003EP1325746A1 Controlled release oxycodone compositions
07/09/2003EP1324749A2 Medicinal aerosol formulations
07/09/2003EP0957897B1 Antiperspirant or deodorant compositions
07/09/2003EP0716613B1 Treatment of helicobacter associated gastroduodenal disease
07/09/2003CN1429225A C10 carbonate substituted taxanes as antitumor agents
07/09/2003CN1429100A Improvements in or relating to delivery of oral drugs
07/09/2003CN1428144A Method for preparing mass micro-capsule
07/09/2003CN1113599C Antimicrobial treatment method for herpes simplex virus and other infectious diseases
07/08/2003US6590076 Isolated polypeptide, of given sequence, comprising at least an immunogenic portion of a tumor antigen; may be used to generate antibodies
07/08/2003US6589570 Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
07/08/2003CA2088300C Oil-in-water emulsions
07/08/2003CA1341434C Compositions and methods for administering therapeutically active compounds
07/03/2003WO2003053942A1 Aryloxyphenyl and arylsulfanylphenyl derivatives
07/03/2003WO2003053920A1 Crystals of bicalutamide and process for their production
07/03/2003WO2003053350A2 Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
07/03/2003WO2003053338A2 Novel chimeric rev, tat, and nef antigens
07/03/2003WO2003030823A3 Combinations for the treatment of immunoinflammatory disorders
07/03/2003WO2003017931A3 Simmondsin processing methods and products
07/03/2003WO2002058734A3 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
07/03/2003WO2002024754A8 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative
07/03/2003US20030125387 Antioestrogens, capable of eliciting complete ablation of the trophic effects of oestrogens; cancer therapy
07/03/2003US20030125340 3-(Amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases
07/03/2003US20030125335 Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
07/03/2003US20030124596 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
07/03/2003US20030124177 Compositions and methods for transdermal oxybutynin therapy
07/03/2003US20030121523 Intraoral discluder device and method for preventing migraine and tension headaches and temporomandibular disorders
07/03/2003CA2470826A1 Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
07/03/2003CA2467118A1 Aryloxyphenyl and arylsulfanylphenyl derivatives
07/02/2003EP1322673A1 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative
07/02/2003EP1322286A2 Polymeric delivery formulations of leuprolide with improved efficacy
07/02/2003EP1175429B1 Halo derivatives of 9-deoxo-9a-aza-9a-homerythromycin a
07/02/2003EP0626864B1 Topical composition containing hyaluronic acid and nsaids
07/02/2003CN1427825A Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
07/02/2003CN1427724A Irradiation of ispaghula
07/02/2003CN1427712A 口腔组合物 Oral compositions
07/02/2003CN1426807A Health care food capable of assisting combustion and decomposing excess fat to reduce body weight
07/02/2003CN1426806A Health care food capable of eliminating honeycomb fat
07/02/2003CN1426805A Health care food capable of promoting female breast well developed
07/02/2003CN1426804A Health care food for reducing body weight due to excess fat in meal
07/02/2003CN1112927C Pharmaceutical composition of corpus albicans emulsifier type lipophilic compound
07/01/2003US6586570 Compositions and methods for the treatment and diagnosis of breast cancer
07/01/2003US6586430 Administering azabicyclo compounds to treat human immunodeficiency virus infections and respiratory system disorders
07/01/2003US6586259 Contacting blood with reagent comprising a marker and mixture of magnetic/non-magnetic particles with ligands; monitoring movement of magnetic particles in response to oscillating/rotating magnetic field; use in diagnosing disease
07/01/2003US6586010 Method for producing agglomerates comprising a core-shell structure
07/01/2003US6585997 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
06/2003
06/26/2003WO2003051851A1 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
06/26/2003WO2003051826A1 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
06/26/2003WO2003051392A2 Streptococcus pneumoniae vaccine
06/26/2003WO2003051385A1 Pharmaceutical formulation comprising cyclosporin and use thereof
06/26/2003WO2003051371A1 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
06/26/2003WO2003051354A1 Method of treatment
06/26/2003WO2003051284A2 Method and device for the delivery of a substance
06/26/2003WO2003051280A2 Intraoral discluder device and method for preventing migraine and tension headaches and temporomandibular disorders
06/26/2003WO2003051272A2 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR GnRH-I AND GnRH-II MODULATION OF T-CELL ACTIVITY, ADHESION, MIGRATION AND EXTRAVASATION
06/26/2003US20030119914 Bis(thio-hydrazide amide) compounds; anticancer agents
06/26/2003US20030119786 Combinations for the treatment of immunoinflammatory disorders
06/26/2003US20030118678 Plant extracts as antiproliferative, viricides and antiparasitic agents
06/26/2003US20030118644 A solid forms comprising low molecular weight peptide-based thrombin inhibitor having pH dependent solubility, cellulose or starch as disintegrant fillers; immediate release
06/26/2003US20030118540 Composition
06/26/2003US20030116164 Intraoral discluder device and method for preventing migraine, tension headache, and temporomandibular disorders
06/26/2003CA2473890A1 Methods and pharmaceutical compositions for gnrh-i and gnrh-ii modulation of t-cell activity, adhesion, migration and extravasation
06/26/2003CA2470645A1 Streptococcus pneumoniae vaccine
06/26/2003CA2469786A1 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
06/26/2003CA2464994A1 Method and device for the delivery of a substance
06/25/2003EP1320540A2 Peptidomimetic protease inhibitors
06/25/2003EP1320372A1 Pharmaceutical preparation and method for treatment of diabetes
06/25/2003EP1025125B1 Aggregates of human insulin derivatives
06/25/2003EP0806957B1 Combination therapy for hiv infection using the hiv protease inhibitor indinavir adn the reverse transcriptase inhibitor 3tc together with azt.
06/25/2003CN1426423A Humanized antibodies that sequester amyloid beta peptide
06/25/2003CN1426410A Dual molecules containing peroxide derivative; synthesis and therapeutic applications thereof
06/25/2003CN1426407A N-(heterocyclic)-benzene or pyridine sulphozmides as antithrombotic agents and anticoagulants
06/25/2003CN1426404A Sodium-hydrogen exchangertype 1 inhibitor (NHE-1)
06/24/2003US6583125 Antiulceration effective amount of a substituted cyclodextrin compound and a cytotoxic drug, especially an anticancer drug; side effect reduction
06/24/2003US6583123 Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue
06/24/2003CA2288910C Pyrazolopyrimidinones for sexual dysfunction
06/24/2003CA2130805C Use of mannose phosphates for the treatment of fibrotic disorders
06/19/2003WO2003050108A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
06/19/2003WO2003049718A1 Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist
06/19/2003WO2003049705A2 Use of pramipexole to treat amyotrophic lateral sclerosis
06/19/2003WO2003049703A2 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
06/19/2003WO2003049677A2 Mesoporous permeation layers for use on active electronic matrix devices
06/19/2003WO2000077000A9 New bispidine compounds useful in the treatment of cardiac arrhythmias
06/19/2003US20030114685 Processes for preparing calcium salt forms of statins
06/19/2003US20030114683 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors
06/19/2003US20030114527 Administering an immediate release tablets containing 400 mg of 5-methyl-2-(2'- chloro-6'-fluoroanilino)phenylacetic acid or salts to a patient for the treatment of cyclooxygenase-2 mediated diseases
1 ... 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 ... 295